Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis.
[Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)].
Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor.
The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity.
The prevalence of multiple sclerosis in the city of Santos has remained unaltered for five years.
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design.
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.
AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy.
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Outer retinal changes following acute optic neuritis.
Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients.
Interleukin-10 expression during the acute phase is a putative prerequisite for delayed viral elimination in a murine model for multiple sclerosis.
Socioeconomic status. The relationship with health and autoimmune diseases.
Does Disease-Irrelevant Intrathecal Synthesis in Multiple Sclerosis Make Sense in the Light of Tertiary Lymphoid Organs?
Who receives rehabilitation in canadian long-term care facilities? A cross-sectional study.
Increased Concentrations of Glutamate and Glutamine in Normal-Appearing White Matter of Patients with Multiple Sclerosis and Normal MR Imaging Brain Scans.
Bone health and multiple sclerosis.
Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature.
Cerebral venous thrombosis after lumbar puncture and intravenous high dose corticosteroids: A case report of a childhood multiple sclerosis.
BREMSO: a simple score to predict early the natural course of multiple sclerosis.
Suicide risk in multiple sclerosis: A systematic review of current literature.
Advanced MRI in multiple sclerosis: current status and future challenges.
Bilateral Vision Loss Responsive to Corticosteroids.
MicroRNA regulation of lymphocyte tolerance and autoimmunity.
Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis.
Pages
« first
‹ previous
…
240
241
242
243
244
245
246
247
248
…
next ›
last »